Literature DB >> 21472302

Reduction of pancreatic cancer cell viability and induction of apoptosis mediated by siRNA targeting DNMT1 through suppression of total DNA methyltransferase activity.

Min Xu1, Jun Gao, Yi Qi Du, Dao-Jian Gao, Yu Qi Zhang, Zhao Shen Li, You Li Zhang, Yan Fang Gong, Ping Xu.   

Abstract

Aberrant methylation leads to epigenetic changes in human genes that may cause carcinogenesis. DNA methyltransferase 1 (DNMT1) plays an important role in maintaining DNA methylation patterns during genomic DNA replication. To understand the role of this protein in pancreatic cancer cell growth and apoptosis, small interfering RNA (siRNA) oligonucleotides were used to knockdown DNMT1 expression in pancreatic cancer PaTu8988 cells. We found that the DNMT1 siRNA markedly decreased DNMT1 expression and total DNA methyltransferase activity in the cells. Upon the inhibition of DNMT1 expression, the proliferation of the tumor cells was inhibited. Tumor cell growth was arrested in the S-phase of the cell cycle and cells underwent apoptosis. The expression of p21 was up-regulated and the ratio of Bax/Bcl-2 expression was increased after DNMT1 knockdown in PaTu8988 cells. Furthermore, DNMT1 siRNA caused demethylation of the tumor suppressor gene hMLH1, resulting in its re-expression in PaTu8988 cells. The results of this study suggest that DNMT1 siRNA oligonucleotides are candidates for further evaluation as therapeutic tools for the clinical control of pancreatic cancer.

Entities:  

Year:  2010        PMID: 21472302     DOI: 10.3892/mmr_00000320

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis.

Authors:  J Huang; A Stewart; B Maity; J Hagen; R L Fagan; J Yang; D E Quelle; C Brenner; R A Fisher
Journal:  Oncogene       Date:  2013-09-02       Impact factor: 9.867

2.  Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression.

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

Review 3.  Emerging role of different DNA methyltransferases in the pathogenesis of cancer.

Authors:  Pengcheng Liu; Fan Yang; Lizhi Zhang; Ying Hu; Bangjie Chen; Jianpeng Wang; Lei Su; Mingyue Wu; Wenjian Chen
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

4.  LncRNA SNHG1 promotes sepsis-induced myocardial injury by inhibiting Bcl-2 expression via DNMT1.

Authors:  Rui Zhang; Zequn Niu; Jie Liu; Xiaoyan Dang; Hui Feng; Jiangli Sun; Longfei Pan; Zhuo Peng
Journal:  J Cell Mol Med       Date:  2022-06-09       Impact factor: 5.295

5.  Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression.

Authors:  Jun Gao; Lihua Wang; Jinkang Xu; Jianming Zheng; Xiaohua Man; Hongyu Wu; Jin Jin; Kaixuan Wang; Huasheng Xiao; Shude Li; Zhaoshen Li
Journal:  J Exp Clin Cancer Res       Date:  2013-11-05

6.  Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells.

Authors:  Wenwen Zhou; Huying Chen; Xiuli Hong; Xiaoqing Niu; Quanyi Lu
Journal:  Oncol Lett       Date:  2014-08-26       Impact factor: 2.967

7.  Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.

Authors:  Hamid Ali Nagi Al-Jamal; Siti Asmaa Mat Jusoh; Rosline Hassan; Muhammad Farid Johan
Journal:  BMC Cancer       Date:  2015-11-07       Impact factor: 4.430

Review 8.  Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Hui Li Ang; Farid Hashemi; Ali Zarrabi; Amirhossein Zabolian; Kiavash Hushmandi; Masoud Delfi; Haroon Khan; Milad Ashrafizadeh; Gautam Sethi; Alan Prem Kumar
Journal:  Cells       Date:  2021-11-29       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.